Previous 10 | Next 10 |
Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate ...
Insider buying decreased last week. Notable Insider Buys: PennyMac Financial Services, Inc., GTY Technology Holdings Inc., Apartment Investment and Management Company, Arcus Biosciences, Inc., and Elastic N.V. Notable Insider Sells: MP Materials Corp., Ulta Beauty, Inc., Facebook,...
The following slide deck was published by Arcus Biosciences, Inc. in conjunction with this event. For further details see: Arcus Biosciences (RCUS) Presents At Cowen 41st Annual Healthcare Virtual Conference - Slideshow
Arcus Biosciences (RCUS): Q4 GAAP EPS of -$0.82 misses by $0.11.Revenue of $9.49M (-2.7% Y/Y) beats by $0.68M.Press Release For further details see: Arcus Biosciences EPS misses by $0.11, beats on revenue
- Multiple key data read-outs expected for 2021, including the ARC-7 interim analysis in 2Q21 - Domvanalimab’s advancement into a registrational study coupled with recent IND clearance for AB308, Arcus’s FcR-enabled anti-TIGIT antibody, reinforces Arcus’s ...
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming 2021 virtual investor conferences: 10th Annual SVB Leerink Global Healthcare ...
Arcus Biosciences (RCUS) announced that Gilead Sciences (GILD) increased its ownership in the company to 19.5% from ~13% through the purchase of 5.65M additional shares at $39/share."The proceeds from this financing will support and enable the acceleration of our development plans for our fou...
- Gilead to purchase additional shares in Arcus, increasing its ownership to 19.5%, further aligning the two companies - Proceeds of $220 million to support and accelerate Arcus’s comprehensive clinical development plans - Increase in ownership does not impact a...
Arcus is founded by Terry Rosen, a successful biopharma entrepreneur. It has novel programs in oncology, which have evinced considerable big pharma interest. Current price is high, although it may be quite justified. For further details see: Arcus Biosciences: Highly Val...
Arcus Biosciences (RCUS) posts positive preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI).The ongoing, open-lab...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...